Treatment of XXXX with @entity1773 .

@entity1 @entity24987 @entity308 @entity8046 @entity2358 @entity4790 @entity2033 @entity7776 @entity1773 @entity8684 @entity22
Seventeen @entity1 with choreiform, athetoid, or @entity2358 , or with spasmodic torticollis, were treated with @entity1773 in doses of 25 to 200 mg daily for periods varying from two weeks to more than six months. Randomized @entity8046   film of the @entity1 ' @entity2358 , taken before, during, and after treatment was assessed individually by seven  blind' observers. Eight @entity1 were judged improved; two had @entity2033 , two @entity8684 , two @entity24987 , one hemiballismus, and one spasmodic torticollis. Four of the eight improved @entity1 have continued taking the drug for longer than six months. In a second study seven @entity1 with @entity2033 were treated for two weeks each with @entity1773 (50 mg t.d.s.) and with @entity7776 (100 mg t.d.s.) and the results assessed by the same method. The @entity4790 of six of these @entity1 were strikingly improved with @entity1773 therapy, but @entity7776 had no effect. @entity1773 is an effective agent for the suppression of choreiform and @entity2358 . It is only slightly effective in the treatment of @entity8684 and spasmodic torticollis. Drowsiness, @entity22 , and @entity308 were the most conspicuous unwanted effects, and these may limit the clinical usefulness of the drug.
